Engagement encouraging multinational food retailers and brand manufacturers to…
The Access to Medicine Index ranks 20 of the world’s largest research-based pharmaceutical companies on the basis of how they manage risks and opportunities related to access to medicine in low- and middle-income countries. The collaborative engagement is a long-term engagement project for tracking the progress of pharmaceutical companies towards SDG 3 by 2030. The company-specific opportunities included in the company report cards of the Access to Medicine Index forms the basis for engagement and tracking progress. 90+ investors have confirmed participation in the collaborative engagement. The list of participating investors can be found in the FAQ.
The Access to Medicine Index measures a range of value drivers within the pharmaceutical business model, including governance, R&D, pricing and compliance. The collaborative engagement covers the 19 listed companies in the 2018 Access to Medicine Index. These companies together account for approximately 60-70% of global pharmaceutical revenues.
Expanding access to medicine will help pharma companies enhance shareholder value in several ways:
- Unlock growth potential in emerging markets by reaching new populations.
- Mitigate the risk of unethical conduct.
- Enhance corporate reputations.
- Contribute to the creation of healthy societies.
Companies covered in the collaborative engagement: AbbVie Inc., Astellas Pharma Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Co., Daiichi-Sankyo Co. Ltd., Eisai Co. Ltd., Eli Lilly & Co., Gilead Sciences Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck KGaA, Merck & Co., Novartis AG, Novo Nordisk A/S, Pfizer Inc., Roche Holding AG, Sanofi, Takeda Pharmaceutical Co. Ltd.